Glomerulonephritis Treatment Market, Global Outlook and Forecast 2022-2028
Report Code: KNJ1281644 No. of Pages: 104 Category: Pharmaceuticals and Healthcare
Publisher: Date of Publish:
Publisher: Date of Publish:
This report contains market size and forecasts of Glomerulonephritis Treatment in Global, including the following market information:
Global Glomerulonephritis Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Glomerulonephritis Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
ACH-5228 Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Glomerulonephritis Treatment include Achillion Pharmaceuticals Inc, Anthera Pharmaceuticals Inc, Biogen Inc, Bristol-Myers Squibb Company, Cellmid Ltd, ChemoCentryx Inc, Complexa Inc, Dimerix Bioscience Pty Ltd and GlaxoSmithKline Plc, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Glomerulonephritis Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Glomerulonephritis Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Glomerulonephritis Treatment Market Segment Percentages, by Type, 2021 (%)
ACH-5228
AMY-101
Atacicept
Avacopan
AVX-002
Global Glomerulonephritis Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Glomerulonephritis Treatment Market Segment Percentages, by Application, 2021 (%)
Home Care
Clinic
Hospital
Global Glomerulonephritis Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Glomerulonephritis Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Glomerulonephritis Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Glomerulonephritis Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Achillion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
Bristol-Myers Squibb Company
Cellmid Ltd
ChemoCentryx Inc
Complexa Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Merck KGaA
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Takeda
Visterra Inc
1 Introduction to Research & Analysis Reports
1.1 Glomerulonephritis Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Glomerulonephritis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Glomerulonephritis Treatment Overall Market Size
2.1 Global Glomerulonephritis Treatment Market Size: 2021 VS 2028
2.2 Global Glomerulonephritis Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Glomerulonephritis Treatment Players in Global Market
3.2 Top Global Glomerulonephritis Treatment Companies Ranked by Revenue
3.3 Global Glomerulonephritis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Glomerulonephritis Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Glomerulonephritis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Glomerulonephritis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Glomerulonephritis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Glomerulonephritis Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Glomerulonephritis Treatment Market Size Markets, 2021 & 2028
4.1.2 ACH-5228
4.1.3 AMY-101
4.1.4 Atacicept
4.1.5 Avacopan
4.1.6 AVX-002
4.2 By Type - Global Glomerulonephritis Treatment Revenue & Forecasts
4.2.1 By Type - Global Glomerulonephritis Treatment Revenue, 2017-2022
4.2.2 By Type - Global Glomerulonephritis Treatment Revenue, 2023-2028
4.2.3 By Type - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Glomerulonephritis Treatment Market Size, 2021 & 2028
5.1.2 Home Care
5.1.3 Clinic
5.1.4 Hospital
5.2 By Application - Global Glomerulonephritis Treatment Revenue & Forecasts
5.2.1 By Application - Global Glomerulonephritis Treatment Revenue, 2017-2022
5.2.2 By Application - Global Glomerulonephritis Treatment Revenue, 2023-2028
5.2.3 By Application - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Glomerulonephritis Treatment Market Size, 2021 & 2028
6.2 By Region - Global Glomerulonephritis Treatment Revenue & Forecasts
6.2.1 By Region - Global Glomerulonephritis Treatment Revenue, 2017-2022
6.2.2 By Region - Global Glomerulonephritis Treatment Revenue, 2023-2028
6.2.3 By Region - Global Glomerulonephritis Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Glomerulonephritis Treatment Revenue, 2017-2028
6.3.2 US Glomerulonephritis Treatment Market Size, 2017-2028
6.3.3 Canada Glomerulonephritis Treatment Market Size, 2017-2028
6.3.4 Mexico Glomerulonephritis Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Glomerulonephritis Treatment Revenue, 2017-2028
6.4.2 Germany Glomerulonephritis Treatment Market Size, 2017-2028
6.4.3 France Glomerulonephritis Treatment Market Size, 2017-2028
6.4.4 U.K. Glomerulonephritis Treatment Market Size, 2017-2028
6.4.5 Italy Glomerulonephritis Treatment Market Size, 2017-2028
6.4.6 Russia Glomerulonephritis Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Glomerulonephritis Treatment Market Size, 2017-2028
6.4.8 Benelux Glomerulonephritis Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Glomerulonephritis Treatment Revenue, 2017-2028
6.5.2 China Glomerulonephritis Treatment Market Size, 2017-2028
6.5.3 Japan Glomerulonephritis Treatment Market Size, 2017-2028
6.5.4 South Korea Glomerulonephritis Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Glomerulonephritis Treatment Market Size, 2017-2028
6.5.6 India Glomerulonephritis Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Glomerulonephritis Treatment Revenue, 2017-2028
6.6.2 Brazil Glomerulonephritis Treatment Market Size, 2017-2028
6.6.3 Argentina Glomerulonephritis Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Glomerulonephritis Treatment Revenue, 2017-2028
6.7.2 Turkey Glomerulonephritis Treatment Market Size, 2017-2028
6.7.3 Israel Glomerulonephritis Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Glomerulonephritis Treatment Market Size, 2017-2028
6.7.5 UAE Glomerulonephritis Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Achillion Pharmaceuticals Inc
7.1.1 Achillion Pharmaceuticals Inc Corporate Summary
7.1.2 Achillion Pharmaceuticals Inc Business Overview
7.1.3 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
7.1.4 Achillion Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.1.5 Achillion Pharmaceuticals Inc Key News
7.2 Anthera Pharmaceuticals Inc
7.2.1 Anthera Pharmaceuticals Inc Corporate Summary
7.2.2 Anthera Pharmaceuticals Inc Business Overview
7.2.3 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
7.2.4 Anthera Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.2.5 Anthera Pharmaceuticals Inc Key News
7.3 Biogen Inc
7.3.1 Biogen Inc Corporate Summary
7.3.2 Biogen Inc Business Overview
7.3.3 Biogen Inc Glomerulonephritis Treatment Major Product Offerings
7.3.4 Biogen Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.3.5 Biogen Inc Key News
7.4 Bristol-Myers Squibb Company
7.4.1 Bristol-Myers Squibb Company Corporate Summary
7.4.2 Bristol-Myers Squibb Company Business Overview
7.4.3 Bristol-Myers Squibb Company Glomerulonephritis Treatment Major Product Offerings
7.4.4 Bristol-Myers Squibb Company Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.4.5 Bristol-Myers Squibb Company Key News
7.5 Cellmid Ltd
7.5.1 Cellmid Ltd Corporate Summary
7.5.2 Cellmid Ltd Business Overview
7.5.3 Cellmid Ltd Glomerulonephritis Treatment Major Product Offerings
7.5.4 Cellmid Ltd Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.5.5 Cellmid Ltd Key News
7.6 ChemoCentryx Inc
7.6.1 ChemoCentryx Inc Corporate Summary
7.6.2 ChemoCentryx Inc Business Overview
7.6.3 ChemoCentryx Inc Glomerulonephritis Treatment Major Product Offerings
7.6.4 ChemoCentryx Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.6.5 ChemoCentryx Inc Key News
7.7 Complexa Inc
7.7.1 Complexa Inc Corporate Summary
7.7.2 Complexa Inc Business Overview
7.7.3 Complexa Inc Glomerulonephritis Treatment Major Product Offerings
7.7.4 Complexa Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.7.5 Complexa Inc Key News
7.8 Dimerix Bioscience Pty Ltd
7.8.1 Dimerix Bioscience Pty Ltd Corporate Summary
7.8.2 Dimerix Bioscience Pty Ltd Business Overview
7.8.3 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Major Product Offerings
7.8.4 Dimerix Bioscience Pty Ltd Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.8.5 Dimerix Bioscience Pty Ltd Key News
7.9 GlaxoSmithKline Plc
7.9.1 GlaxoSmithKline Plc Corporate Summary
7.9.2 GlaxoSmithKline Plc Business Overview
7.9.3 GlaxoSmithKline Plc Glomerulonephritis Treatment Major Product Offerings
7.9.4 GlaxoSmithKline Plc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.9.5 GlaxoSmithKline Plc Key News
7.10 Merck KGaA
7.10.1 Merck KGaA Corporate Summary
7.10.2 Merck KGaA Business Overview
7.10.3 Merck KGaA Glomerulonephritis Treatment Major Product Offerings
7.10.4 Merck KGaA Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.10.5 Merck KGaA Key News
7.11 Omeros Corp
7.11.1 Omeros Corp Corporate Summary
7.11.2 Omeros Corp Business Overview
7.11.3 Omeros Corp Glomerulonephritis Treatment Major Product Offerings
7.11.4 Omeros Corp Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.11.5 Omeros Corp Key News
7.12 Pfizer Inc
7.12.1 Pfizer Inc Corporate Summary
7.12.2 Pfizer Inc Business Overview
7.12.3 Pfizer Inc Glomerulonephritis Treatment Major Product Offerings
7.12.4 Pfizer Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.12.5 Pfizer Inc Key News
7.13 Pharmalink AB
7.13.1 Pharmalink AB Corporate Summary
7.13.2 Pharmalink AB Business Overview
7.13.3 Pharmalink AB Glomerulonephritis Treatment Major Product Offerings
7.13.4 Pharmalink AB Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.13.5 Pharmalink AB Key News
7.14 Ra Pharmaceuticals Inc
7.14.1 Ra Pharmaceuticals Inc Corporate Summary
7.14.2 Ra Pharmaceuticals Inc Business Overview
7.14.3 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
7.14.4 Ra Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.14.5 Ra Pharmaceuticals Inc Key News
7.15 Retrophin Inc
7.15.1 Retrophin Inc Corporate Summary
7.15.2 Retrophin Inc Business Overview
7.15.3 Retrophin Inc Glomerulonephritis Treatment Major Product Offerings
7.15.4 Retrophin Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.15.5 Retrophin Inc Key News
7.16 Rigel Pharmaceuticals Inc
7.16.1 Rigel Pharmaceuticals Inc Corporate Summary
7.16.2 Rigel Pharmaceuticals Inc Business Overview
7.16.3 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Major Product Offerings
7.16.4 Rigel Pharmaceuticals Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.16.5 Rigel Pharmaceuticals Inc Key News
7.17 Takeda
7.17.1 Takeda Corporate Summary
7.17.2 Takeda Business Overview
7.17.3 Takeda Glomerulonephritis Treatment Major Product Offerings
7.17.4 Takeda Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.17.5 Takeda Key News
7.18 Visterra Inc
7.18.1 Visterra Inc Corporate Summary
7.18.2 Visterra Inc Business Overview
7.18.3 Visterra Inc Glomerulonephritis Treatment Major Product Offerings
7.18.4 Visterra Inc Glomerulonephritis Treatment Revenue in Global Market (2017-2022)
7.18.5 Visterra Inc Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
NEED Help?
If you need any help or guidance, please feel free to call us.
USA : +1 (661) 636 6162
INDIA : +91 9325802062
or
Write us on : sales@kandjmarketresearch.com